The offering will dilute existing shareholders by roughly 10%, likely pressuring the stock near term. Monitor the stock's reaction at the open; the $20.50 offering price may act as a near-term floor. Proceeds extend the cash runway for DMD and DM1 clinical programs, reducing near-term financing risk.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 22 $23.21entry
- T+1 · 4mo ago +2.93%α +4.16% · $23.89
- T+5 · 4mo ago +8.14%α +10.54% · $25.10
- T+20 · 3mo ago +15.38%α +12.48% · $26.78
- T+60 · 5w ago −34.12%α −37.39% · $15.29
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gross proceeds of $375.15 million. The offering will dilute existing shareholders by approximately 9-11% (including the underwriter option) and provides additional cash runway for the company's clinical-stage neuromuscular programs.
Key Financial Metrics
Key Facts
- Offering of 18,300,000 shares at $20.50 per share, upsized from original terms.
- Gross proceeds expected to be $375,150,000 before expenses.
- Underwriters have a 30-day option to purchase up to an additional 2,745,000 shares.
- Expected to close on or about July 23, 2026.
- Joint book-running managers: Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James.
Financial Impact
Gross proceeds of $375.15 million from the sale of 18.3 million shares (plus up to 2.745 million additional shares via underwriter option). Dilution to existing shareholders is significant given the company's pre-revenue status.
Risk Factors
- Significant dilution to existing shareholders (approximately 9.6% base, up to 11% with overallotment).
- Potential downward pressure on stock price as new shares enter the market.
- Clinical-stage company with no approved products; offering proceeds may be consumed before reaching key milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3331062 |
Track record
54 reports on DYN
12 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers